Loading
Loki Therapeutics
Loki Therapeutics uses weakened Listeria bacteria to deliver a piece of the tetanus vaccine into tumour cells, so that immune cells primed by childhood tetanus vaccination recognise and attack the tumour. Its first trial, with gemcitabine, is in pancreatic cancer that cannot be removed by surgery.
Overview
Loki Therapeutics is an immuno-oncology company whose AWAKE technology and Myeloid Mediated Delivery platform use an attenuated bacterial vector to carry childhood recall antigens, such as tetanus toxoid, selectively into tumours and metastases, so that existing memory T cells from tetanus vaccination target tumour cells displaying the antigen. Preclinical work in pancreatic cancer models with Listeria-delivered tetanus toxoid drew trade press coverage in March 2022. Its candidate Lm-LLO-TT is in a phase 1 study with gemcitabine in unresectable pancreatic ductal adenocarcinoma, run with the National Cancer Institute (NCT07828236), posted in September 2026 and not yet recruiting when read. The company's chief executive and co-founder is Christopher Bradley. Its first registered cancer trial, NCT07828236, was posted on ClinicalTrials.gov in September 2026.
Notes
- Read on 29 October 2026: lokitx.com home, science, pipeline, news and contact pages (the pipeline and contact pages show no text) and a February 2021 PR Newswire release, whose dateline gives Long Island City, New York; the current headquarters was not confirmed.
- Founding year and financing not stated on the pages read. The registry contact domain belongs to a regulatory consultancy, not the company.
- Trial facts from the ClinicalTrials.gov record NCT07828236, read on 29 October 2026.
Connected
4Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
lokitx.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/